metastaticcastration-resistantprostatecancer相关论文
Chemotherapy in prostate cancer (PCa) has undergone dramatic landscape changes.While earlier studies utilized varying ch......
In 2004, docetaxel was approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). For the ne......
Surface-enhanced Raman spectroscopy of serum predicts sensitivity to docetaxel-based chemotherapy in
Docetaxel-based chemotherapy, as the first-line treatment for metastatic castration-resistant prostate cancer (mCRPC), h......
